Table 1.
Characteristics of study patients and waitlisted patients on the deceased donor kidney transplant waiting list as of November 30, 2016
| Characteristic | n=5365 Study Patients | n=3112a Waitlisted Patients with ≥10 yr of Dialysis Exposure on November 30, 2016 | P Value |
|---|---|---|---|
| Duration of dialysis exposure, yr | |||
| Median (Q1–Q3) | 12.6 (11.1–14.6)b | 11.8 (10.7–13.6) | <0.001 |
| Age at 10-yr anniversary, yr | |||
| Median (Q1,Q3) | 48 (40–57) | 53 (43–60) | <0.001 |
| Age categories, yr | |||
| 18–39 | 25 | 15 | <0.001 |
| 40–49 | 30 | 27 | |
| 50–59 | 28 | 34 | |
| 60–64 | 11 | 14 | |
| 65–69 | 6 | 10 | |
| Women | 46 | 46 | 0.51 |
| Race | |||
| White non-Hispanic | 20 | 19 | 0.001 |
| White Hispanic | 17 | 21 | |
| Black | 55 | 52 | |
| Other | 8 | 8 | |
| Cause of kidney disease | |||
| Diabetes | 13 | 19 | <0.001 |
| Glomerular | 19 | 24 | |
| Hypertension | 33 | 32 | |
| Polycystic | 4 | 4 | |
| Other | 31 | 21 | |
| Body mass index, kg/m2 | |||
| <25 | 39 | 32 | <0.001 |
| 25–29.9 | 30 | 29 | |
| 30–34.9 | 19 | 19 | |
| ≥35 | 12 | 20 | |
| Comorbid conditions | |||
| Angina | 4 | 3 | 0.07 |
| Cerebrovascular disease | 2 | 3 | 0.19 |
| Peripheral vascular disease | 4 | 4 | 0.10 |
| Cancer | 4 | 3 | 0.07 |
| ABO blood group | |||
| A | 25 | 23 | 0.07 |
| B | 18 | 20 | |
| AB | 3 | 2 | |
| O | 54 | 55 | |
| Peak PRA % | |||
| 0 | 27 | 19 | <0.001 |
| 1–29 | 19 | 11 | |
| 30–79 | 13 | 10 | |
| 80–89 | 4 | 3 | |
| 90–94 | 3 | 2 | |
| 95–97 | 4 | 4 | |
| 98 | 2 | 3 | |
| 99 | 15 | 26 | |
| 100 | 13 | 22 | |
| OPTN region | |||
| 1 | 3 | 4 | <0.001 |
| 2 | 10 | 11 | |
| 3 | 18 | 20 | |
| 4 | 11 | 11 | |
| 5 | 19 | 21 | |
| 6 | 2 | 2 | |
| 7 | 7 | 8 | |
| 8 | 4 | 3 | |
| 9 | 9 | 8 | |
| 10 | 7 | 5 | |
| 11 | 10 | 9 | |
| Median household income (Q1–Q3) | $42,891 ($33,193–$57,003) | $44,714 ($34,252–$59,633) | <0.001 |
| Insurance | |||
| Private | 15 | 21 | <0.001 |
| Medicare | 72 | 63 | |
| Medicaid | 11 | 13 | |
| Other | 2 | 3 | |
| Education | <0.001 | ||
| Less than high school | 50 | 55 | |
| Postsecondary | 29 | 33 | |
| Unknown | 21 | 12 | |
| Previous transplant | 15 | 25 | <0.001 |
| Expected post-transplant survival, % | |||
| 1–20 | 26 | 11 | <0.001 |
| 21–40 | 31 | 26 | |
| 41–60 | 18 | 20 | |
| 61–80 | 14 | 22 | |
| 81–100 | 11 | 21 |
Income could not be calculated in 8% of the study patients and 7% of current waitlisted patients. Body mass index is missing in 2% of study patients and 2% of current waitlisted patients. Percentages are shown unless otherwise indicated. Q1,Q3, first and third quartile; PRA, panel reactive antibody; OPTN, Organ Procurement and Transplantation Network.
a
Excludes n=562 study patients who were on the waiting list on November 30, 2016.
b
Duration of dialysis exposure before waitlisting (years). Patients waitlisted before the start of dialysis treatment were assigned a value of zero.